"label","rationale","uuid:ID","description","id","name","instanceType"
"","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","98ba7b90-b3f5-4d07-88e7-f8046ba0c9e8","The main design for the study","StudyDesign_1","Study Design 1","StudyDesign"
